Table 1 Characteristics of included studies
Author, year | Intervention (dose, schedule) | Comparison (description) | Patients (N) | Age (years) | Male (%) | Cytogenetic risk group, N (%) | ECOG score | Bone marrow blasts, median (range) | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|
Azacitidine | |||||||||
Fenaux et al. [15] | Azacitidine: subcutaneously 75 mg/m2/day for 7 days Q28 days for at least 6 cycles | CCR (BSC, LDAC 20 mg/m2/day for 14 days Q28 days for at least 6 cycles, IC) | Intervention: 55 Comparison: 58 | Intervention: 73 (64–89) Comparison: 73 (64–91) | Intervention: 62.1 Comparison: 56.6 | Intermediate: 81 (71.7%) Normal: 52 (46.0%) Poor risk: 27 (23.9%) Missing: 5 (4.4%) | 0–1: 107 (94.7%) 2: 4 (3.5%) Missing: 2 (1.8%) | Intervention: 23.0 (20.0–34.0) Comparison: 23.1 (13.0–68.9) | 40 |
Dombret et al. [16] | Azacitidine: subcutaneously 75 mg/m2/day for 7 days Q28 days for at least 6 cycles | CCR (BSC, LDAC 20 mg/m2/day for 14 days Q28 days for at least 6 cycles, IC) | Intervention: 241 Comparison: 247 | Intervention: 75 (64–91) Comparison: 75 (65–89) | Intervention: 57.7 Comparison: 60.3 | Intermediate: 306 (63.1%) Normal: – Poor risk: 174 (35.8%) Missing: – | 0-1: 375(76.8%) 2: 113(23.2%) missing:– | Intervention: 70.0 (2.0–100.0) Comparison: 72.0 (2.0–100.0) > 50%: 366 (75.0%) | 40 |
Decitabine | |||||||||
Kantarjian et al. [17] | Decitabine: intravenously 20 mg/m2 QD for 5 days, every 4 weeks | TC (supportive care,or cytarabine 20 mg/m2 QD for 10 days, every 4 weeks) | Intervention: 242 Comparison: 243 | Intervention: 73 (64–89) Comparison: 73 (64–91) | Intervention: 62.1 Comparison: 56.6 | Intermediate: 306 (63.1%) Normal: – Poor risk: 174 (35.8%) Missing: – | 0–1: 367 (75.7%) 2: 118 (24.3%) Missing: – | 20–30%: 123 (25.2%) > 30–50%: 141 (29.3%) > 50%: 206 (42.7%) | 36 |